O
CRBP icon

OrbiMed’s Corbus Pharmaceuticals CRBP Stock Holding History

OrbiMed’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,667
Closed -$2.94M – 149
2020
Q2 		$2.94M Buy
+11,667
New +$2.36M 0.04% 128

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

OrbiMed's CRBP Position: Q1 2026 in Review

OrbiMed increased its Corbus Pharmaceuticals (CRBP) stake by 8.8% in Q1 2026, buying an estimated $1.18M and bringing the position to 1,737,287 shares worth $16.3M. The position accounts for 0.32% of the portfolio, ranked #62.

OrbiMed first reported a position in CRBP in Q3 2024 and has held it in 7 quarters since. The position peaked at $18.8M in Q3 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • OrbiMed held 1,737,287 shares of Corbus Pharmaceuticals worth $16.3M as of Q1 2026.
  • OrbiMed bought 140,000 Corbus Pharmaceuticals shares in Q1 2026, an estimated $1.18M.
  • Corbus Pharmaceuticals made up 0.32% of OrbiMed's portfolio in Q1 2026, its #62 holding.
  • OrbiMed first reported a position in Corbus Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
  • OrbiMed's Corbus Pharmaceuticals position peaked at $18.8M in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.